In last trading session, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) saw 0.34 million shares changing hands with its beta currently measuring 0.25. Company’s recent per share price level of $0.44 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $12.28M. That closing price of IPA’s stock is at a discount of -490.91% from its 52-week high price of $2.60 and is indicating a premium of 20.45% from its 52-week low price of $0.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.75 million shares which gives us an average trading volume of 463.46K if we extend that period to 3-months.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
ImmunoPrecise Antibodies Ltd’s shares saw a change of -74.27% in year-to-date performance and have moved 5.39% in past 5-day. ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) showed a performance of -25.42% in past 30-days. Number of shares sold short was 0.15 million shares which calculate 0.45 days to cover the short interests.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Statistics highlight that ImmunoPrecise Antibodies Ltd is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -65.89% of value to its shares in past 6 months, showing an annual growth rate of 61.54% while that of industry is 26.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 0.20% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.62M for the same. And 2 analysts are in estimates of company making revenue of 4.81M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.23% during past 5 years.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Insiders are in possession of 12.06% of company’s total shares while institution are holding 5.75 percent of that, with stock having share float percentage of 6.53%. Investors also watch the number of corporate investors in a company very closely, which is 5.75% institutions for ImmunoPrecise Antibodies Ltd that are currently holding shares of the company. INGALLS & SNYDER LLC is the top institutional holder at IPA for having 1.3 million shares of worth $1.31 million. And as of 2024-06-30, it was holding 5.0209 of the company’s outstanding shares.
The second largest institutional holder is RENAISSANCE TECHNOLOGIES LLC, which was holding about 63910.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.2477 of outstanding shares, having a total worth of $64549.0.
